Literature DB >> 27578042

Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease.

Bas W G van Rhijn1, Maximilian Burger2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27578042     DOI： 10.1038/nrurol.2016.165

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Authors:  Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner
Journal:  Eur Urol       Date:  2016-06-17       Impact factor: 20.096

2.  Challenges in non-muscle invasive bladder cancer: lessons from a regional review.

Authors:  Mark T Siddins; Vun Vun Wong; Jude Thomas Fitzgerald; Lisa Jane Bamberg
Journal:  ANZ J Surg       Date:  2011-11-10       Impact factor: 1.872

3.  Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study.

Authors:  Paolo Gontero; Marco Oderda; Vincenzo Altieri; Riccardo Bartoletti; Tommaso Cai; Renzo Colombo; Antonio Curotto; Savino Di Stasi; Massimo Maffezzini; Stefania Tamagno; Vincenzo Serretta; Filippo Sogni; Carlo Terrone; Alessandro Tizzani; Giuseppe Morgia; Vincenzo Mirone; Giorgio Carmignani
Journal:  Urol Int       Date:  2010-12-30       Impact factor: 2.089

4.  Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.

Authors:  Karim Chamie; Christopher S Saigal; Julie Lai; Jan M Hanley; Claude M Setodji; Badrinath R Konety; Mark S Litwin
Journal:  Cancer       Date:  2011-07-11       Impact factor: 6.860

5.  [Quality of care in patients with newly diagnosed bladder cancer: a prospective assessment in northern Germany].

Authors:  C Reek; M Rink; M Bloch; J Hansen; F K Chun; A Schneider; J Busche; M Fisch
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

6.  Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta.

Authors:  Geoffrey T Gotto; Melissa A Shea-Budgell; J Dean Ruether
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

7.  Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Authors:  Ralph Madeb; Dragan Golijanin; Katia Noyes; Susan Fisher; Judith J Stephenson; Stacey R Long; Joy Knopf; Gary H Lyman; Edward M Messing
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

8.  Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project.

Authors:  George J Huang; Ann S Hamilton; Mary Lo; John P Stein; David F Penson
Journal:  J Urol       Date:  2008-06-11       Impact factor: 7.450

Review 9.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.

Authors:  Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan
Journal:  J Urol       Date:  2016-06-16       Impact factor: 7.450

10.  Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

Authors:  J Alfred Witjes; Joan Palou; Mark Soloway; Donald Lamm; Ashish M Kamat; Maurizio Brausi; Raj Persad; Roger Buckley; Marc Colombel; Andreas Böhle
Journal:  BJU Int       Date:  2013-03-01       Impact factor: 5.588
  10 in total
  10 in total

1.  Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC).

Authors:  Jean Carlo F Datovo; Wilmar Azal Neto; Gustavo B Mendonça; Danilo L Andrade; Leonardo O Reis
Journal:  World J Urol       Date:  2019-02-25       Impact factor: 4.226

Review 2.  Guideline of guidelines: non-muscle-invasive bladder cancer.

Authors:  Solomon L Woldu; Aditya Bagrodia; Yair Lotan
Journal:  BJU Int       Date:  2017-01-24       Impact factor: 5.588

3.  The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer.

Authors:  Danijel Sikic; Helge Taubert; Johannes Breyer; Markus Eckstein; Veronika Weyerer; Bastian Keck; Jennifer Kubon; Wolfgang Otto; Thomas S Worst; Maximilian C Kriegmair; Philipp Erben; Arndt Hartmann; Bernd Wullich; Ralph M Wirtz; Sven Wach
Journal:  Cancer Manag Res       Date:  2021-08-20       Impact factor: 3.989

4.  Nonadherence to Multimodality Cancer Treatment Guidelines in the United States.

Authors:  Leila T Tchelebi; Biyi Shen; Ming Wang; Louis Potters; Joseph Herman; Daniel Boffa; Joel E Segel; Henry S Park; Nicholas G Zaorsky
Journal:  Adv Radiat Oncol       Date:  2022-03-08

5.  Attention to detail and a permissive set-up: crucial for an effective TURBT.

Authors:  Paramananthan Mariappan
Journal:  Nat Rev Urol       Date:  2021-05       Impact factor: 14.432

6.  Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

Authors:  K Kent Chevli; Neal D Shore; Andrew Trainer; Angela B Smith; Daniel Saltzstein; Yaron Ehrlich; Jay D Raman; Boris Friedman; Richard D'Anna; David Morris; Brian Hu; Mark Tyson; Alexander Sankin; Max Kates; Jennifer Linehan; Douglas Scherr; Steven Kester; Michael Verni; Karim Chamie; Lawrence Karsh; Arnold Cinman; Andrew Meads; Soumi Lahiri; Madlen Malinowski; Nimrod Gabai; Sunil Raju; Mark Schoenberg; Elyse Seltzer; William C Huang
Journal:  J Urol       Date:  2021-08-26       Impact factor: 7.450

7.  Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013.

Authors:  Kelly K Bree; Yong Shan; Patrick J Hensley; Niyati Lobo; Chengrui Hu; Douglas S Tyler; Karim Chamie; Ashish M Kamat; Stephen B Williams
Journal:  JAMA Netw Open       Date:  2022-03-01

8.  Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non-muscle-invasive Bladder Cancer.

Authors:  Anouk E Hentschel; Christian J Blankvoort; Judith Bosschieter; André N Vis; R Jeroen A van Moorselaar; Judith E Bosmans; Jakko A Nieuwenhuijzen
Journal:  Eur Urol Open Sci       Date:  2022-01-17

9.  High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.

Authors:  Danijel Sikic; Helge Taubert; Ralph M Wirtz; Johannes Breyer; Markus Eckstein; Veronika Weyerer; Jennifer Kubon; Philipp Erben; Christian Bolenz; Maximilian Burger; Arndt Hartmann; Bernd Wullich; Sven Wach; Bastian Keck
Journal:  Life (Basel)       Date:  2021-06-30

10.  Non-muscle invasive bladder cancer: Are epicrises the 'Bermuda Triangle' of information transfer?

Authors:  Steffen Lebentrau; Matthias May; Anne-Kathrin Wick; Michael Roiner; Marcella Mathew; Christian Gilfrich; Martin Schostak
Journal:  Cent European J Urol       Date:  2017-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.